GVK Biosciences Private Limited (GVK BIO) today inaugurated the GVK BIO Wyeth Hyderabad Chemistry Center, a built-to-suit research center for Wyeth Pharmaceuticals located in Hyderabad. The Research center was inaugurated by Dr. Robert Ruffolo, Ph.D., President, Wyeth Research, in the presence of Mr. David Hopper, the Consul General, United States Consulate, Chennai, Mr. G V Krishna Reddy, Chairman, GVK Group, Mr. D.S.Brar, Chairman, GVK BIO and Mr. G V Sanjay Reddy, Managing Director, GVK BIO.
A team of 200 synthetic chemists and scientists are working on cutting-edge research in this state-of-the-art facility. The facility is equipped with the latest high-end scientific equipment and instrumentation. The GVK BIO Wyeth Hyderabad Chemistry Center, located at Nacharam is comparable to any international research center.
GVK BIO and Wyeth entered into a collaborative research agreement in 2006. Wyeth selected GVK BIO after a global worldwide search for a suitable chemistry partner. GVK BIO was selected for the strength of their management team, research philosophy, and expertise in the area of Synthetic Organic Chemistry. The current activities include the synthesis of reference standards, building blocks, intermediates, analogues, focused libraries and screening libraries. GVK BIO has a proven capability and track record in delivering value-added scientific services on time.
Mr. G V Krishna Reddy, Chairman, GVK Group said “GVK BIO is our group’s first venture outside of Infrastructure. We are happy with the way GVK BIO has grown rapidly to become India’s leading Contract Research Organization”.
Dr. Ruffolo said “Wyeth has a large discovery portfolio resulting in a growing need for strong medicinal chemistry. By working with GVK BIO as a partner, we are able to tap into the huge chemistry talent pool in India and to work globally on a 24-hour basis. This partnership significantly increases our chemistry capacity and complements our already strong in-house synthetic chemistry efforts.”
“Through this Research partnership, Wyeth has given a strong vote of confidence not only to GVK BIO but on a larger platform to India. Based on the success of the current Medicinal Chemistry projects, we look forward to growing our collaboration in other areas” said Mr. D.S.Brar, Chairman, GVK BIO.
Mr. G.V.Sanjay Reddy said, “GVK BIO has made available the best scientific talent for Wyeth. The facility, human resources and equipment reflect high quality of science and productivity levels. The collaboration has been a win-win for both Wyeth and GVK BIO.”
GVK BIO will be responsible for designing synthetic routes for new molecules, carrying out the synthesis and characterization of target molecules for Wyeth.
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
About GVK BIO
GVK Biosciences, India’s premier Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.